Walleye Capital
LXEO icon

Walleye Capital’s Lexeo Therapeutics LXEO Stock Holding History

Walleye Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Buy
+73,868
New +$400K ﹤0.01% 3056
2025
Q1 		– Sell
-61,930
Closed -$407K – 4738
2024
Q4 		$407K Buy
+61,930
New +$488K ﹤0.01% 3153

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Walleye Capital's LXEO Position: Q2 2026 in Review

Walleye Capital opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 73,868 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #3056 among its holdings. This is a return to the name: Walleye Capital previously reported a position in LXEO as recently as Q4 2024.

Walleye Capital first reported a position in LXEO in Q4 2024 and has held it in 2 quarters since. The position peaked at $407K in Q4 2024. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Walleye Capital held 73,868 shares of Lexeo Therapeutics worth $344K as of Q2 2026.
  • Lexeo Therapeutics was a new Walleye Capital position in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3056 holding.
  • Walleye Capital first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Walleye Capital's Lexeo Therapeutics position peaked at $407K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.